PEX10 and prostate carcinoma: In order to further explore the role of PEX10 in prostate cancer and enzalutamide resistant prostate cancer, we first analyzed the expression of PEX10 in the TCGA database, and we found that the expression level of PEX10 was significantly increased in prostate cancer tissues (Fig. 2A), and its expression level was significantly positively correlated with Gleason score (Fig. 2B), subsequently, we obtained the same results in patient specimens (Fig. S2A, B).